Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent to participate (or whose legal representative has done so on their behalf)
• People who agree to allow stored tumour tissue samples from their diagnosis to be used for the study (exceptions may be possible if samples are unavailable — confirm with trial site)
• People aged between 18 and 80 years old
• People over 70 years old must have a good general health and activity level score (Karnofsky score of 80 or above) and a low score on a transplant-specific health assessment tool (HCT-CI of 2 or below) — confirm with trial site
• People with a general health and activity level score (Karnofsky) of 70% or above
• People diagnosed with one of the following blood cancers who are suitable for a stem cell transplant from a well-matched donor (8 out of 8 match, related or unrelated):
  • Acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL) that is in complete remission, with less than 5% abnormal cells in the bone marrow
  • Myelodysplastic syndrome with less than 10% abnormal cells in the bone marrow
  • A type of bone marrow disorder called myeloproliferative neoplasm (other than myelofibrosis) that requires a stem cell transplant
  • Chronic myelomonocytic leukaemia (CMML)
• People with a haemoglobin (red blood cell) level of 9 g/dL or above, tested within 30 days before starting treatment (without a blood transfusion in the 14 days before that test, unless low levels are caused by the disease)
• People with liver function test results within acceptable ranges, tested within 30 days before starting treatment (confirm specific values with trial site)
• People with kidney function within an acceptable range, tested within 30 days before starting treatment (confirm with trial site)
• People with a heart pumping function (ejection fraction) of 50% or above, tested within 28 days before starting treatment
• People able to do breathing tests must have lung function results at 50% or above of the expected level, tested within 28 days before starting treatment
• People unable to do breathing tests must have a blood oxygen level above 92% while breathing normal room air, tested within 28 days before starting treatment
• People who test negative for HIV, hepatitis C, and active hepatitis B, tested within 30 days before starting treatment (people living with HIV who are on effective treatment with an undetectable virus level in the past 6 months may still be eligible)
• People who have had a tuberculosis (TB) test within 30 days before starting treatment (people with a positive TB test will need further assessment and may receive preventive treatment after the transplant — confirm with trial site)
• People who meet other standard infection screening requirements set by the institution, tested within 28 days before starting treatment
• Women who could become pregnant must have a negative pregnancy test within 30 days before starting treatment
• People of childbearing potential (men and women) must agree to use effective contraception or avoid sexual activity that could lead to pregnancy throughout the study and for at least 3 months after the last dose of study treatment

Who may not be able to join:

• People who have previously had an allogeneic (donor) stem cell transplant
• People who have received chemotherapy, radiation, biological therapy, or immunotherapy within 14 days before starting the study treatment (note: preparative treatment given as part of the transplant process is not counted as an exclusion)
• People who are taking other experimental drugs for the prevention of a transplant complication called graft-versus-host disease (GVHD)
• People who are taking herbal medicines or supplements
• People with a known allergy to substances that are chemically or biologically similar to the study treatment
• People with a serious illness that is not well controlled
• People with an active infection that is not responding to antibiotic treatment
• People with another active cancer (though people with a past or current cancer that is unlikely to interfere with the study may still be eligible — confirm with trial site)
• Women who are pregnant or breastfeeding
• People who are not expected to be available for follow-up appointments at the study institution for at least 100 days after the transplant
• People with any other condition that the investigator believes would make participation unsafe
• People who, in the investigator's opinion, may not be able to follow all study procedures and requirements

Important: Always verify eligibility with the trial site directly before applying.